< Go back

Cryoablation for recurrent renal tumors after primary nephron-sparing surgery using an innovative liquid nitrogen-based cryogenic device


Sagi Shprits¹, Robert Sachner², Simona Croitoru², Karina Dorfman², Ofir Avitan¹, Zaher Bahouth¹, Amnon Zisman³ and Ofer

¹ Department of Urology, Bnai Zion Medical Center, Haifa, 3339419, Israel
² Department of Radiology, Bnai Zion Medical Center, Haifa, 3339419, Israel
³ Department of Urology, Assaf Harofeh Medical Center, Be’er Ya’akov, 3339419, Israel


Published results:
Of 7 patients with tumor recurrence after nephron-sparing surgery, none of the treated tumor lesions demonstrated contrast enhancement or growth on follow up imaging indicating a 100% oncologic success. Only three adverse events were recorded. Investigators found cryoablation with the ProSense™ system is feasible and effective, with excellent renal function preservation and without major complications.